SA patient activists wants court to consider medicines access issue in Sanofi patent case
This article was originally published in Scrip
A South African patent dispute concerning Sanofi's anticancer Taxotere (docetaxel) and Cipla's cut-price generic version of the product is expected to attract global attention, with the local HIV-focused advocacy group Treatment Action Campaign (TAC) urging the court to consider the right of access to healthcare services when it decides on the case.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.